ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Tokyo considers trials of parasite drug for COVID-19

Ivermectin tablets to be assessed for possible home use

The Tokyo Metropolitan Government plans to conduct clinical trials of the anti-parasitic drug Ivermectin to assess its effectiveness in treating COVID-19 patients with mild symptoms.   © Reuters

TOKYO -- The Tokyo Metropolitan Government plans to conduct clinical trials of the anti-parasitic drug Ivermectin at metropolitan and public hospitals to assess its effectiveness against COVID-19, Nikkei has learned.

Clinical trials will be conducted on patients with mild symptoms. Patients who are hospitalized mostly have moderate or serious symptoms. The metropolitan government will finalize the details of the study, including the size and duration of clinical trials, after the infection situation settles down.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more